BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905 [PMID: 29209131 DOI: 10.3748/wjg.v23.i44.7899]
URL: https://www.wjgnet.com/1007-9327/full/v23/i44/7899.htm
Number Citing Articles
1
Shahid Sarwar, Shandana Tarique, Abdul Aleem, Anwaar A. Khan. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in PakistanEuropean Journal of Gastroenterology & Hepatology 2019; 31(8): 1035 doi: 10.1097/MEG.0000000000001376
2
An Update on National Consensus Practice Guidelines for the Treatment of Hepatitis C & Literature Review in Epidemiology of Hepatitis C in Pakistan - 2022Journal of Rawalpindi Medical College 2024; 1(1) doi: 10.37939/jrmc.v1i1.2533
3
Saba Khaliq, Syed Raza. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in PakistanMedicina 2018; 54(5): 80 doi: 10.3390/medicina54050080
4
Massimo Giuseppe Colombo, Erkin Isakovich Musabaev, Umed Yusupovich Ismailov, Igor A Zaytsev, Alexander V Nersesov, Igor Anatoliyevich Anastasiy, Igor Alexandrovich Karpov, Olga A Golubovska, Kulpash S Kaliaskarova, Ravishankar AC, Sanjay Hadigal. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regionsWorld Journal of Gastroenterology 2019; 25(29): 3897-3919 doi: 10.3748/wjg.v25.i29.3897
5
Uzma Saleem, Nosheen Aslam, Rida Siddique, Shabnoor Iqbal, Maria Manan. Hepatitis C virus: Its prevalence, risk factors and genotype distribution in PakistanEuropean Journal of Inflammation 2022; 20 doi: 10.1177/1721727X221144391
6
Attiya S Rahman, Muhammad Amir, Qaiser Jamal, Mehwish Riaz , Komal Fareed, Muhammad Siddiqui. End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and DaclatasvirCureus 2023;  doi: 10.7759/cureus.38833